Four things to know:
1. NVG-291 is a linear peptide comprised of common amino acids.
2. Its Phase 1 safety and pharmacokinetic study in healthy subjects will begin in the first quarter of 2020.
3. The expansion of its Phase 1 trial on spinal cord injury patients will begin in the second half of 2020.
4. A Phase 2 multiple sclerosis trial is set for the first quarter of 2021.
More articles on biologics:
‘A dream come true’: Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker’s spine division stands to gain from 5 acquisitions
